Skip to content
Screener

Ironwood Pharmaceuticals IRWD Gross Profit

Discontinued — last reported Q4 '20

Gross Profit at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$54.21M+10.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$265.21M-40.8%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$800.7M+42.1%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$52.96M+82.3%
Scilex Holding Company logo
Scilex Holding CompanySCLX
$4.17M+15.1%
Viatris logo
ViatrisVTRS
$1.46B+9.3%

Other financials

Income statement

See full
Revenue$113.0M+32.6%
Operating income$79.3M+75.0%
Net income$51.3M+117%
EPS (diluted)$0.31+121%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$11.9M-94.4%
Total equity-$161.8M+47.5%
Total assets$285.1M-16.9%

Cash flow

See full
Operating cash flow$58.3M—
CapEx-—
Free cash flow$74.6M+390%

Valuation

See full
Market cap$713.84M+427%
Enterprise value$646.58M+152%
P/E5.5×—
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%—
Operating margin60.1%+36.4pp
Net margin33.4%+31.1pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity0×-0.5×
Current ratio6.1×+5.2×

Where this comes from

Calculated from Ironwood Pharmaceuticals’s reported figures.

$116.7Mtotal revenue−$897.0Ktotal cost of revenue=$115.78M

The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 16, 2023. Open the filing →

Filed
Feb 16, 2023
Fiscal year
FY2022
Accession
0001558370-23-001462

FAQ

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.